The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]


Variant: NM_005629.4(SLC6A8):c.116G>A (p.Gly39Asp)

CA16616458

410221 (ClinVar)

Gene: SLC6A8
Condition: creatine transporter deficiency
Inheritance Mode: X-linked inheritance
UUID: c417ca3f-9c6f-4b3b-84cc-991f7426a1d8
Approved on: 2022-06-06
Published on: 2022-10-08

HGVS expressions

NM_005629.4:c.116G>A
NM_005629.4(SLC6A8):c.116G>A (p.Gly39Asp)
NC_000023.11:g.153688690G>A
CM000685.2:g.153688690G>A
NC_000023.10:g.152954145G>A
CM000685.1:g.152954145G>A
NC_000023.9:g.152607339G>A
NG_012016.1:g.5394G>A
NG_012016.2:g.5394G>A
ENST00000253122.10:c.116G>A
ENST00000253122.9:c.116G>A
ENST00000458354.5:c.-3+125C>T
ENST00000480693.1:n.64+125C>T
NM_001142805.1:c.116G>A
NM_005629.3:c.116G>A
NM_001142805.2:c.116G>A

Uncertain Significance

Met criteria codes 2
PM2 BP4

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen Cerebral Creatine Deficiency Syndromes Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for SLC6A8 Version 1

Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
Cerebral Creatine Deficiency Syndromes VCEP
The NM_005629.4(SLC6A8):c.116G>A (p.Gly39Asp) variant in SLC6A8 is a missense variant predicted to cause substitution of Glycine for Aspartic Acid at amino acid 39 (p.Gly39Asp). This variant is absent from gnomAD v2.1.1, therefore PM2_Supporting criteria is applicable. The computational predictor REVEL gives a score of 0.107 which is below the threshold of 0.25, and does not predict a damaging effect on SLC6A8 function, and SpliceAI predicts no impact on splicing (BP4). This variant has not been previously reported in affected individuals in the literature. There is a ClinVar entry for this variant (Variation ID:410221). In summary, this variant meets the criteria to be classified as a Variant of Uncertain Significance for Creatine Transporter Deficiency based on the ACMG/AMP criteria applied, as specified by the ClinGen Cerebral Creatine Deficiency Syndromes Variant Curation Expert Panel (Specifications Version 1.1.0): PM2_Supporting, BP4. (Classification approved by the ClinGen CCDS VCEP on June 6, 2022).
Met criteria codes
PM2
This variant is absent from gnomAD v2.1.1, therefore PM2_Supporting criteria is applicable.
BP4
The computational predictor REVEL gives a score of 0.107 which is below the threshold of 0.25, and does not predict a damaging effect on SLC6A8 function, and SpliceAI predicts no impact on splicing (BP4).
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.